Company Profile

Immunetics Inc
Profile last edited on: 4/24/2020      CAGE: 1D7W6      UEI: N1KPNMTNJFP6

Business Identifier: Immunoassays for infectious diseases: Lyme disease
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

27 Drydock Avenue 6th Floor
Boston, MA 02210
   (617) 896-9100
Location: Single
Congr. District: 08
County: Suffolk

Public Profile

In October 2016, Imunetics was acquired by Oxford Immunotec Global PLC (Nasdaq:OXFD) in a cash and future payouts transaction. Immunetics Inc., a biotechnology company, works in the space of development of immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. With a strong international presence, the firm's products include the Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company's products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antibodies to protective antigen of anthrax in human and animal samples; and BacTx Test for the bacterial contamination of platelets. In February of 2016, Immunetics announced the launch of its MycoDx™ assay for invasive fungal infections. Such infections are particularly dangerous to immunocompromised patients, including transplant recipients and those undergoing cancer therapies. MycoDx™ is a multiplex molecular assay developed by Immunetics that can identify 21 fungal pathogens in a whole blood sample.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $3,581,495
Project Title: Molecular Detection of Invasive Fungal Infections
2017 2 NIH $5,202,100
Project Title: Immunoassay for Diagnosis of Babesia Infection
2016 2 NIH $3,467,249
Project Title: Rapid, Near-Transfusion Test for Bacteria in Platelet Units
2016 2 NIH $3,575,325
Project Title: Rapid Test for Recent Hiv Infection and Incidence Panels for Assay Evaluation
2016 2 NIH $3,600,000
Project Title: Rapid Point Of-Care Test for Lyme Serodiagnosis Based on Novel Ultra-Sensitive De

Key People / Management

  Andrew E Levin -- President and Scientific Director

  John Yonkin -- CEO

  Joan Clifford -- Director, Clinical Affairs

  Patricia Ellen Garrett

  Victor Kovalenko

  Neil X Krueger -- Research Manager

  Nancy Levy

  Lynda S Mungo -- QA/QC Manager

  Richard Pinkowitz -- Vice President

  Reginaldo P Priolo